A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes
- PMID: 1833467
- DOI: 10.1016/0022-1759(91)90291-m
A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes
Abstract
A flow cytometric assay (FCA) was developed to measure complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes. It was possible to measure these parameters accurately with intra- and interassay coefficients of variation of 2.0% and 6.5% respectively. The method was able to discriminate between low and high levels of erythrocyte CR1, C3d and C4d. Comparison with a previously described RIA method gave excellent correlation coefficients with r2 values of 0.94, 0.93 and 0.91 for CR1, C3d and C4d respectively. The flow cytometric assay was used to measure CR1, C3d and C4d on the erythrocytes of 98 healthy individuals and the 95% upper limits for C3d and C4d were established. There was a wide distribution of CR1 levels amongst these individuals but their C3d and C4d levels were low and often not above background. The possible application of this method in clinical medicine is discussed.
Similar articles
-
Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.Clin Exp Immunol. 1993 Nov;94(2):286-90. doi: 10.1111/j.1365-2249.1993.tb03445.x. Clin Exp Immunol. 1993. PMID: 8222319 Free PMC article.
-
Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.Arthritis Rheum. 1989 Mar;32(3):259-64. doi: 10.1002/anr.1780320305. Arthritis Rheum. 1989. PMID: 2522783
-
Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.Arthritis Rheum. 2010 Mar;62(3):837-44. doi: 10.1002/art.27267. Arthritis Rheum. 2010. PMID: 20187154 Free PMC article.
-
Complement receptors.Year Immunol. 1989;4:231-40. Year Immunol. 1989. PMID: 2538973 Review. No abstract available.
-
Complement receptor type 1 (C3b/C4b receptor; CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21).Curr Top Microbiol Immunol. 1990;153:83-98. doi: 10.1007/978-3-642-74977-3_5. Curr Top Microbiol Immunol. 1990. PMID: 2153507 Review. No abstract available.
Cited by
-
Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients.Immunobiology. 2021 May;226(3):152093. doi: 10.1016/j.imbio.2021.152093. Epub 2021 May 9. Immunobiology. 2021. PMID: 34022670 Free PMC article.
-
Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.Front Immunol. 2019 Apr 12;10:773. doi: 10.3389/fimmu.2019.00773. eCollection 2019. Front Immunol. 2019. PMID: 31031764 Free PMC article.
-
Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.Adv Drug Deliv Rev. 2021 Nov;178:113992. doi: 10.1016/j.addr.2021.113992. Epub 2021 Sep 29. Adv Drug Deliv Rev. 2021. PMID: 34597748 Free PMC article. Review.
-
Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA).Pharmaceutics. 2022 Apr 6;14(4):805. doi: 10.3390/pharmaceutics14040805. Pharmaceutics. 2022. PMID: 35456638 Free PMC article. Review.
-
Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.Clin Exp Immunol. 1993 Nov;94(2):286-90. doi: 10.1111/j.1365-2249.1993.tb03445.x. Clin Exp Immunol. 1993. PMID: 8222319 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources